NKGen Biotech, Inc. Reports Third Quarter 2023 Financial
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease,...
Source: globenewswire.com
Stay updated with breaking news from Operating Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– SNK01 Phase I autologous clinical program demonstrated improvement in neuroinflammation and cognitive function in patients with Alzheimer’s Disease,...
Unaudited Condensed Consolidated Financial Statements Condensed Balance Sheets as of June 30, 2023 ...